RNA vs BCAX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 01, 2026

RNA

59.8
AI Score
VS
RNA Wins

BCAX

51.0
AI Score

Investment Advisor Scores

RNA

60score
Recommendation
HOLD

BCAX

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RNA BCAX Winner
Net Income -36.82M -111.65M RNA
Operating Income -39.90M -120.19M RNA
ROE -17.2% -23.8% RNA
ROA -13.1% -21.8% RNA
Total Assets 280.51M 512.24M BCAX
Cash 72.33M 96.60M BCAX
Current Ratio 8.73 11.59 BCAX
Free Cash Flow -37.20M -81.83M RNA

Relative Price Performance (Last 90 Days)

RNA 1M: -43.3% · 3M: -38.7% BCAX 1M: -22.9% · 3M: -37.9%

Current Technical Phase

RNA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 24

RSI (14): 24.1 · Price: $7.97

BCAX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -10.7%), weak momentum, RSI 26

RSI (14): 25.6 · Price: $18.16

Fundamentals Snapshot

Metric RNA BCAX
Market Cap — —
Forward P/E -1.0 -5.2
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.2% 0.0%
Gross Margin -0.6% —
Operating Margin -7.5% 0.0%
EPS -5.44 -3.07
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.